Status:
NOT_YET_RECRUITING
The Effects of Metformin on Morbidity and Mortality in Elderly Patients
Lead Sponsor:
Hamilton Health Sciences Corporation
Conditions:
Burns
Eligibility:
All Genders
60-99 years
Phase:
PHASE2
Brief Summary
Elderly patients have an increased susceptibility to burns and a substantial mortality that has not significantly changed over the last three decades. Elderly burn patients not only have an augmented ...
Eligibility Criteria
Inclusion
- Aged 60 - 99 years of age.
- ≥5% total body surface area (TBSA) burn.
- Admitted to burn center ≤ 120 hours post-burn injury.
- At least one surgical intervention likely required.
- Provide written informed consent.
Exclusion
- Death upon admission.
- Decision not to treat due to burn injury severity.
- Presence of anoxic brain injury that is not expected to result in complete recovery.
- Pre-existing renal failure (eGFR is \< 30 mL/min).
- Severe liver disease (Child-Pugh C).
- Pre-existing insulin-dependent type II diabetes.
- Clinical contraindication to give metformin.
- Allergy to metformin or insulin.
- History of lactic acidosis while receiving metformin treatment.
Key Trial Info
Start Date :
November 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2029
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT04530058
Start Date
November 1 2024
End Date
March 1 2029
Last Update
October 2 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hamilton Health Sciences Centre
Hamilton, Ontario, Canada, L8L 2X2